John M. Evans - 29 Jan 2026 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
CEO, Director
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol
BEAM
Transactions as of
29 Jan 2026
Net transactions value
-$1,410,028
Form type
4
Filing time
02 Feb 2026, 16:05:08 UTC
Previous filing
03 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Evans John M. CEO, Director C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE By: /s/ Christine Bellon, Attorney-in-fact 02 Feb 2026 0001786304

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $12,955 +19,336 +2% $0.6700 1,006,003 29 Jan 2026 Direct F1
transaction BEAM Common Stock Options Exercise $3,795 +5,664 +0.56% $0.6700 1,011,667 29 Jan 2026 Direct F1
transaction BEAM Common Stock Sale $476,801 -16,333 -1.6% $29.19 995,334 29 Jan 2026 Direct F1, F2
transaction BEAM Common Stock Sale $257,781 -8,667 -0.87% $29.74 986,667 29 Jan 2026 Direct F1, F3
transaction BEAM Common Stock Options Exercise $16,750 +25,000 +2.5% $0.6700 1,011,667 30 Jan 2026 Direct F1
transaction BEAM Common Stock Sale $624,672 -22,094 -2.2% $28.27 989,573 30 Jan 2026 Direct F1, F4
transaction BEAM Common Stock Sale $84,274 -2,906 -0.29% $29.00 986,667 30 Jan 2026 Direct F1
holding BEAM Common Stock 103,000 29 Jan 2026 By John M. Evans, III 2018 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -19,336 -100% $0.000000 0 29 Jan 2026 Common Stock 19,336 $0.6700 Direct F1, F5
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -5,664 -5.7% $0.000000 93,672 29 Jan 2026 Common Stock 5,664 $0.6700 Direct F1, F6
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -25,000 -27% $0.000000 68,672 30 Jan 2026 Common Stock 25,000 $0.6700 Direct F1, F6
transaction BEAM Stock Option (Right to Buy) Award $0 +180,000 $0.000000 180,000 31 Jan 2026 Common Stock 180,000 $27.62 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $28.65 to $29.64 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $29.66 to $29.92 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $27.87 to $28.82 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022, and December 31, 2022.
F6 On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.
F7 This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.